Edwards Lifesciences (EW) Tops Q2 EPS by 1c, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Grand Canyon Education places CFO on leave amid stock trade probe
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- Funds sell $44bn in semiconductors on AI concerns
Edwards Lifesciences (EW) shares decline as growth disappoints investors
July 27, 2023 12:19 PM EDTShares of Edwards Lifesciences (NYSE: EW) declined after it reported second quarter results. Despite solid earnings per share and revenue, growth rates disappointed investors.
Edwards Lifesciences reported second quarter sales that were slightly above consensus at $1.53 billion. At $0.66, EPS topped consensus by a penny.
The company expects full year 2023 sales to be between $5.9 billion and $6.1 billion. For the year, the company expects transcatheter aortic... More
